Published

Psilocybin microdosing in the United States: Insights from a nationally representative survey

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Addiction
Date: 2026-03-08
Source: Crossref
DOI: 10.1111/add.70368
PubMed: 41795902

Authors

Priest Michelle Kilmer Beau Ramchand Rajeev Atshan Samer

Watch author

Derived topics and classifications

psilocybin Microdosing Observational Study Observational Study

Citation graph

9 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.

Open citation network

10.3390/molecules26102948 10.1080/21507740.2024.2303154 10.7326/annals-24-03145 10.1111/add.16575 10.1001/jamahealthforum.2024.1653 10.1007/s00213-020-05477-0 10.1080/02791072.2019.1683260 10.1177/02698811231225609 10.1001/jamahealthforum.2024.1262

Indexed papers citing this DOI

Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA2026-06-15 Psilocybin microdosing in the United States: Insights from a nationally representative survey2026-03-08

Related papers

A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionClinicalTrials.gov · 2026-07-31 Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)ClinicalTrials.gov · 2026-05-14